Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
P24347
UPID:
MMP11_HUMAN
Alternative names:
Matrix metalloproteinase-11
Alternative UPACC:
P24347; Q5FX24; Q6PEZ6; Q9UC26
Background:
Stromelysin-3, also known as Matrix metalloproteinase-11, is a protein that may play a pivotal role in the progression of epithelial malignancies. Its unique structure and function distinguish it from other matrix metalloproteinases, making it a subject of intense study in the field of cancer research.
Therapeutic significance:
Understanding the role of Stromelysin-3 could open doors to potential therapeutic strategies. Its involvement in epithelial malignancies highlights its importance as a target for drug discovery efforts aimed at combating cancer.